FFPE

The Boston-based firm recently shared data indicating its RNA-seq panel can help guide colorectal cancer treatment with its in-licensed investigational drugs.

The signature may be useful for guiding treatment strategy based on patients' prognoses, and with further validation, may even be useful for predicting response to specific drugs.